Status:
RECRUITING
AIMS Cancer Outcomes Study
Lead Sponsor:
Advanced Integrative Medical Science Institute
Conditions:
Neoplasms
Neoplasm Malignant
Eligibility:
All Genders
Brief Summary
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative...
Detailed Description
It is estimated that between 50 and 80% of cancer patients in the United States (US) supplement their conventional medical treatment regimen with some form of complementary or alternative medicine (CA...
Eligibility Criteria
Inclusion
- A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or
- An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute;
- If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment;
- If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient;
- A confirmed diagnosis of cancer based on medical oncology medical records.
Exclusion
- Patients not diagnosed with cancer;
- Telehealth patients;
- Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires;
- Unwilling to participate in the AIMS Institute observational study.
Key Trial Info
Start Date :
May 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04495790
Start Date
May 18 2020
End Date
December 31 2030
Last Update
February 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AIMS Institute
Seattle, Washington, United States, 98102